Xiangyang Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiangyang Wang has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Li Yang
Department of Gastroenterology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, PR China.
2 shared publications Min Li
Department of Gastroenterology, Hunan Provincial People's Hospital The First Affiliated Hospital of Hunan Normal University Changsha China
2 shared publicationsZhiyuan Chen
Department of Gastroenterology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, PR China
2 shared publicationsHonglin Ju
Department of Gastroenterology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, PR China
1 shared publicationLi Yang
Department of Gastroenterology, Hunan Provincial People’s Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China
1 shared publication- Peng Liu
Department of Gastroenterology, Hunan Provincial People’s Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China
1 shared publication
Latest Publications
- 12 June 2025
- p. 18949
PU.1 aggravates hepatic sinusoidal obstruction syndrome by upregulating PTBP1 and activating the Wnt/β-catenin pathway.
Hepatic sinusoidal obstruction syndrome (HSOS) is a disease characterized by damage to hepatic sinusoidal endothelial cells (HSECs). This research investigates the role and regulatory pathway of PU box-binding protein (PU.1) in the progression of HSOS. We established an in vivo HSOS model through peritoneal administration of monocrotaline (MCT). Primary murine HSECs were isolated and treated with various concentrations of MCT to establish an in vitro HSOS model. PU.1 knockdown was achieved using lentiviral shRNA constructs, and its impact on oxidative stress, PTBP1 expression, β-catenin mRNA stability, and Wnt/β-catenin signaling was evaluated through kits, RT-qPCR, and western blot. Dual-luciferase and chromatin immunoprecipitation assays were conducted to assess the interaction between PU.1 and the PTBP1 promoter. The molecular association between PTBP1 and β-catenin mRNA was confirmed through RNA pull-down and RIP assays. PU.1 was upregulated in MCT-induced HSOS, contributing to elevated oxidative stress and activation of the Wnt/β-catenin pathway. PU.1 directly enhanced PTBP1 transcription, which stabilized β-catenin mRNA and sustained Wnt/β-catenin signaling. PU.1 knockdown alleviated oxidative stress, reduced liver damage, and disrupted the PTBP1-β-catenin interaction, leading to Wnt/β-catenin activity inhibition. Overexpression of PTBP1 reversed the protective effects of PU.1 knockdown, reinstating oxidative stress and reactivating Wnt/β-catenin signaling. PU.1 facilitated HSOS pathogenesis by promoting the transcriptional activity of PTBP1 and activating the Wnt/β-catenin pathway. Targeting PU.1 can serve as a promising therapeutic strategy for reducing oxidative stress and liver damage in HSOS.
- 12 June 2025
- p. 18949
PU.1 aggravates hepatic sinusoidal obstruction syndrome by upregulating PTBP1 and activating the Wnt/β-catenin pathway.
Hepatic sinusoidal obstruction syndrome (HSOS) is a disease characterized by damage to hepatic sinusoidal endothelial cells (HSECs). This research investigates the role and regulatory pathway of PU box-binding protein (PU.1) in the progression of HSOS. We established an in vivo HSOS model through peritoneal administration of monocrotaline (MCT). Primary murine HSECs were isolated and treated with various concentrations of MCT to establish an in vitro HSOS model. PU.1 knockdown was achieved using lentiviral shRNA constructs, and its impact on oxidative stress, PTBP1 expression, β-catenin mRNA stability, and Wnt/β-catenin signaling was evaluated through kits, RT-qPCR, and western blot. Dual-luciferase and chromatin immunoprecipitation assays were conducted to assess the interaction between PU.1 and the PTBP1 promoter. The molecular association between PTBP1 and β-catenin mRNA was confirmed through RNA pull-down and RIP assays. PU.1 was upregulated in MCT-induced HSOS, contributing to elevated oxidative stress and activation of the Wnt/β-catenin pathway. PU.1 directly enhanced PTBP1 transcription, which stabilized β-catenin mRNA and sustained Wnt/β-catenin signaling. PU.1 knockdown alleviated oxidative stress, reduced liver damage, and disrupted the PTBP1-β-catenin interaction, leading to Wnt/β-catenin activity inhibition. Overexpression of PTBP1 reversed the protective effects of PU.1 knockdown, reinstating oxidative stress and reactivating Wnt/β-catenin signaling. PU.1 facilitated HSOS pathogenesis by promoting the transcriptional activity of PTBP1 and activating the Wnt/β-catenin pathway. Targeting PU.1 can serve as a promising therapeutic strategy for reducing oxidative stress and liver damage in HSOS.
- Open Access
- 5 March 2025
- Published by Springer Nature in Inflammation
- Vol. 48 (5) , 3130-3145
Baicalein Reduces Pyroptosis of Acinar Cells in Hyperlipidemic Acute Pancreatitis by Inhibiting M1 Polarization of Macrophages via the HMGB1/TLR4/NLRP3 Pathway
Previous studies have shown that baicalein (BAI) can reduce pyroptosis of pancreatic acinar cells (PACs) in hyperlipidemic acute pancreatitis (HAP). This study aimed to elucidate the potential molecular mechanism of PAC pyroptosis mediated by BAI in HAP. A HAP rat model was established via a high-fat diet supplemented with 5% sodium taurocholate. Macrophages were treated with palmitic acid (PA). The rats and cells were treated with BAI. Molecular docking and DARTS assay were used to analyze BAI binding to HMGB1. Co-IP revealed that HMGB1 interacted with TLR4 and NLRP3 and that TLR4 interacted with NLRP3. The interaction between PA-induced macrophages and PACs was evaluated by cell coculture. BAI treatment improved pancreatic lesions, reduced iNOS expression, and decreased the number of M1 macrophages in HAP rats. BAI decreased CD86, HMGB1, NLRP3, ASC, cleaved caspase-1, and GSDMD-N expression in pancreatic tissue and serum IL-1β and IL-18 levels in HAP rats. Molecular docking results and DARTS assays revealed that BAI combined with HMGB1. Co-IP verified that HMGB1 interacted with TLR4 and NLRP3 and that TLR4 interacted with NLRP3. BAI and the HMGB1 inhibitor EP inhibited HMGB1, TLR4, and NLRP3 levels in PA-induced macrophages, increased cell viability, reduced pyroptosis, and ROS release, and inhibited M1 polarization. BAI and EP inhibited PA-induced M1 macrophage polarization and reduced PAC pyroptosis. HMGB1 overexpression partially reversed the effects of BAI on PA-treated macrophages and PACs. Under EP treatment, BAI had no significant effect on the above functions in PA-induced macrophages and PACs. BAI inhibited PA-induced macrophage M1 polarization through the HMGB1/TLR4/NLRP3 pathway, further inhibiting PAC pyroptosis. Our findings provide a theoretical and experimental basis for the molecular mechanism underlying BAI in the treatment of HAP.
- 5 March 2025
- Published by Springer Nature in Inflammation
- Vol. 48 (5) , 3130-3145
Open AccessBaicalein Reduces Pyroptosis of Acinar Cells in Hyperlipidemic Acute Pancreatitis by Inhibiting M1 Polarization of Macrophages via the HMGB1/TLR4/NLRP3 Pathway
Previous studies have shown that baicalein (BAI) can reduce pyroptosis of pancreatic acinar cells (PACs) in hyperlipidemic acute pancreatitis (HAP). This study aimed to elucidate the potential molecular mechanism of PAC pyroptosis mediated by BAI in HAP. A HAP rat model was established via a high-fat diet supplemented with 5% sodium taurocholate. Macrophages were treated with palmitic acid (PA). The rats and cells were treated with BAI. Molecular docking and DARTS assay were used to analyze BAI binding to HMGB1. Co-IP revealed that HMGB1 interacted with TLR4 and NLRP3 and that TLR4 interacted with NLRP3. The interaction between PA-induced macrophages and PACs was evaluated by cell coculture. BAI treatment improved pancreatic lesions, reduced iNOS expression, and decreased the number of M1 macrophages in HAP rats. BAI decreased CD86, HMGB1, NLRP3, ASC, cleaved caspase-1, and GSDMD-N expression in pancreatic tissue and serum IL-1β and IL-18 levels in HAP rats. Molecular docking results and DARTS assays revealed that BAI combined with HMGB1. Co-IP verified that HMGB1 interacted with TLR4 and NLRP3 and that TLR4 interacted with NLRP3. BAI and the HMGB1 inhibitor EP inhibited HMGB1, TLR4, and NLRP3 levels in PA-induced macrophages, increased cell viability, reduced pyroptosis, and ROS release, and inhibited M1 polarization. BAI and EP inhibited PA-induced M1 macrophage polarization and reduced PAC pyroptosis. HMGB1 overexpression partially reversed the effects of BAI on PA-treated macrophages and PACs. Under EP treatment, BAI had no significant effect on the above functions in PA-induced macrophages and PACs. BAI inhibited PA-induced macrophage M1 polarization through the HMGB1/TLR4/NLRP3 pathway, further inhibiting PAC pyroptosis. Our findings provide a theoretical and experimental basis for the molecular mechanism underlying BAI in the treatment of HAP.
- 12 August 2024
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 38 (8) , e23802
mTORC2 knockdown mediates lipid metabolism to alleviate hyperlipidemic pancreatitis through PPARα
Hyperlipidemic pancreatitis (HP) is an inflammatory injury of the pancreas triggered by elevated serum triglyceride (TG) levels. The mechanistic target of rapamycin (mTOR) signaling pathway plays a crucial role in regulating lipid homeostasis and inflammation. This study aimed to investigate whether the activity of mTOR complex 2 (mTORC2) affects the progression of HP and its underlying mechanisms. In vivo, a high‐fat diet and retrograde administration of sodium taurocholate were employed to establish the HP models in rats, with pancreatic tissue pathology evaluated. The expression of Rictor and peroxisome proliferator‐activator receptor (PPAR) was examined. The serum levels of TG, fatty acid metabolites, inflammatory and lipid metabolism‐related factors were determined. In vitro, pancreatic acinar cells (PACs) were exposed to palmitic acid and cholecystokinin‐8. PAC apoptosis, pyroptosis, and ferroptosis were assessed. In the HP models, rats and PACs exhibited upregulated Rictor and downregulated PPARα, and Rictor knockdown promoted PPARα expression. In vivo, Rictor knockdown decreased the serum levels of TG, α‐amylase, total cholesterol, low‐density lipoprotein cholesterol, lactate dehydrogenase, and inflammatory factors, while increasing high‐density lipoprotein cholesterol levels. Rictor knockdown increased ACOX1 and CPT1α and decreased SREBP‐1, CD36, SCD1, ACLY, and ACACA. Rictor knockdown reduced damage to pancreatic tissue structure. In vitro, Rictor knockdown inhibited PAC apoptosis, pyroptosis, and ferroptosis. Treatment with the PPARα antagonist GW6471 abolished the beneficial effects of Rictor knockdown. Rictor/mTORC2 deficiency reduces serum TG levels, maintains lipid homeostasis, and suppresses inflammation by inhibiting PPARα expression. Weakening mTORC2 activity holds promise as a novel therapeutic strategy for HP.
- 12 August 2024
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 38 (8) , e23802
mTORC2 knockdown mediates lipid metabolism to alleviate hyperlipidemic pancreatitis through PPARα
Hyperlipidemic pancreatitis (HP) is an inflammatory injury of the pancreas triggered by elevated serum triglyceride (TG) levels. The mechanistic target of rapamycin (mTOR) signaling pathway plays a crucial role in regulating lipid homeostasis and inflammation. This study aimed to investigate whether the activity of mTOR complex 2 (mTORC2) affects the progression of HP and its underlying mechanisms. In vivo, a high‐fat diet and retrograde administration of sodium taurocholate were employed to establish the HP models in rats, with pancreatic tissue pathology evaluated. The expression of Rictor and peroxisome proliferator‐activator receptor (PPAR) was examined. The serum levels of TG, fatty acid metabolites, inflammatory and lipid metabolism‐related factors were determined. In vitro, pancreatic acinar cells (PACs) were exposed to palmitic acid and cholecystokinin‐8. PAC apoptosis, pyroptosis, and ferroptosis were assessed. In the HP models, rats and PACs exhibited upregulated Rictor and downregulated PPARα, and Rictor knockdown promoted PPARα expression. In vivo, Rictor knockdown decreased the serum levels of TG, α‐amylase, total cholesterol, low‐density lipoprotein cholesterol, lactate dehydrogenase, and inflammatory factors, while increasing high‐density lipoprotein cholesterol levels. Rictor knockdown increased ACOX1 and CPT1α and decreased SREBP‐1, CD36, SCD1, ACLY, and ACACA. Rictor knockdown reduced damage to pancreatic tissue structure. In vitro, Rictor knockdown inhibited PAC apoptosis, pyroptosis, and ferroptosis. Treatment with the PPARα antagonist GW6471 abolished the beneficial effects of Rictor knockdown. Rictor/mTORC2 deficiency reduces serum TG levels, maintains lipid homeostasis, and suppresses inflammation by inhibiting PPARα expression. Weakening mTORC2 activity holds promise as a novel therapeutic strategy for HP.
- 31 December 2022
- Published by Elsevier in Gastroenterology
- Vol. 165 (3) , e1-e3
An Unusual Cause of Portal Hypertension
- 31 December 2022
- Published by Elsevier in Gastroenterology
- Vol. 165 (3) , e1-e3
An Unusual Cause of Portal Hypertension